[
  {
    "ts": "2025-08-07T13:02:00+00:00",
    "headline": "U.S. Active Pharmaceutical Ingredients CDMO Market Report 2025-2030 | Competitive Analysis of Thermo Fisher Scientific, Novo Group, Cambrex, Piramal, Corden, Siegfried, Seqens, SK, Noramco, BSP",
    "summary": "The U.S. Active Pharmaceutical Ingredients CDMO market, valued at USD 25.28 billion in 2024, is projected to grow at a 5.1% CAGR, reaching USD 33.86 billion by 2030. Growth factors include rising demand for innovative drug development, advancements in manufacturing automation, and a focus on biologics and personalized medicine. U.S. Active Pharmaceutical Ingredients CDMO Market U.S. Active Pharmaceutical Ingredients CDMO Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Active Pharmaceu",
    "url": "https://finance.yahoo.com/news/u-active-pharmaceutical-ingredients-cdmo-130200746.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "88651d5b-35cd-3dae-bd63-49c89d8e2a8e",
      "content": {
        "id": "88651d5b-35cd-3dae-bd63-49c89d8e2a8e",
        "contentType": "STORY",
        "title": "U.S. Active Pharmaceutical Ingredients CDMO Market Report 2025-2030 | Competitive Analysis of Thermo Fisher Scientific, Novo Group, Cambrex, Piramal, Corden, Siegfried, Seqens, SK, Noramco, BSP",
        "description": "",
        "summary": "The U.S. Active Pharmaceutical Ingredients CDMO market, valued at USD 25.28 billion in 2024, is projected to grow at a 5.1% CAGR, reaching USD 33.86 billion by 2030. Growth factors include rising demand for innovative drug development, advancements in manufacturing automation, and a focus on biologics and personalized medicine. U.S. Active Pharmaceutical Ingredients CDMO Market U.S. Active Pharmaceutical Ingredients CDMO Market Dublin, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The \"U.S. Active Pharmaceu",
        "pubDate": "2025-08-07T13:02:00Z",
        "displayTime": "2025-08-07T13:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/40588fdf79132c66fa77d1f6c648b845",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "U.S. Active Pharmaceutical Ingredients CDMO Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Kex61BiBZeoENqvS0C1E6Q--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/40588fdf79132c66fa77d1f6c648b845.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7YcbF9j8VoUFs555zJPxgw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/40588fdf79132c66fa77d1f6c648b845.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-active-pharmaceutical-ingredients-cdmo-130200746.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-active-pharmaceutical-ingredients-cdmo-130200746.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-07T12:00:00+00:00",
    "headline": "Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service",
    "summary": "FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of a new testing service for preeclampsia, a sign",
    "url": "https://finance.yahoo.com/news/trinity-biotech-announces-launch-fda-120000059.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c9e04a76-aed7-36ed-8f21-4f87e6fd9f3d",
      "content": {
        "id": "c9e04a76-aed7-36ed-8f21-4f87e6fd9f3d",
        "contentType": "STORY",
        "title": "Trinity Biotech Announces Launch of FDA-cleared Preeclampsia Testing Service",
        "description": "",
        "summary": "FDA-cleared PreClara™ Ratio (sFlt-1/PlGF) biomarker test offers clinicians a crucial tool for managing hypertensive disorders of pregnancy, with potential significant cost savings and improved patient outcomes DUBLIN, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of a new testing service for preeclampsia, a sign",
        "pubDate": "2025-08-07T12:00:00Z",
        "displayTime": "2025-08-07T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/799b0f6ed1100995d056e1c0c7b61a23",
          "originalWidth": 190,
          "originalHeight": 40,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Q5cp.uy5dxiF_1n6JJQ4hg--~B/aD00MDt3PTE5MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/799b0f6ed1100995d056e1c0c7b61a23.cf.webp",
              "width": 190,
              "height": 40,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wRGF2M2327WA3voCdsSkJg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/799b0f6ed1100995d056e1c0c7b61a23.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trinity-biotech-announces-launch-fda-120000059.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trinity-biotech-announces-launch-fda-120000059.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TRIB"
            },
            {
              "symbol": "TMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]